Orexo
18.48 SEK
+2.10 %
Less than 1K followers
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.10 %
-8.97 %
-34.70 %
-38.60 %
-32.68 %
+23.20 %
+71.11 %
-55.66 %
-79.46 %
Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.
Read moreMarket cap
686.65M SEK
Turnover
194.34K SEK
Revenue
26M
EBIT %
-1,356.54 %
P/E
1
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
16/7
2026
Interim report Q2'26
22/10
2026
Interim report Q3'26
4/2
2027
Annual report '26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Report from Orexo AB’s annual general meeting May 7 2026
DNB Carnegie Access: Orexo: Better visibility, few near-term catalysts – Q1 review
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
